Skip to main content
. Author manuscript; available in PMC: 2016 Jul 12.
Published in final edited form as: Neurosurgery. 2011 Dec;69(6):1272–1280. doi: 10.1227/NEU.0b013e3182233e24

FIGURE 2.

FIGURE 2

Progressive disease. A, contrast-enhancing volume of each of the 5 patients with progressive disease after therapy plotted over time. Progressive disease refers to increasing contrast-enhancing volume at ≥1 month after therapy until surgical resection or death. B, serial contrast-enhanced T1-weighted MRI scans from the patient with the greatest progression at 8 months in A showing a rapid increase in contrast enhancement and necrosis at the treatment site and inferior to the treatment (Tx) margin (surgical resection followed the last scan).